264 related articles for article (PubMed ID: 25031296)
1. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
[TBL] [Abstract][Full Text] [Related]
2. Aliskiren enhances the protective effects of valsartan against cardiovascular and renal injury in endothelial nitric oxide synthase-deficient mice.
Yamamoto E; Kataoka K; Dong YF; Nakamura T; Fukuda M; Tokutomi Y; Matsuba S; Nako H; Nakagata N; Kaneko T; Ogawa H; Kim-Mitsuyama S
Hypertension; 2009 Sep; 54(3):633-8. PubMed ID: 19597038
[TBL] [Abstract][Full Text] [Related]
3. Valsartan slows the progression of diabetic nephropathy in db/db mice via a reduction in podocyte injury, and renal oxidative stress and inflammation.
Zhou G; Cheung AK; Liu X; Huang Y
Clin Sci (Lond); 2014 May; 126(10):707-20. PubMed ID: 24195695
[TBL] [Abstract][Full Text] [Related]
4. Aliskiren enhances protective effects of valsartan against type 2 diabetic nephropathy in mice.
Dong YF; Liu L; Lai ZF; Yamamoto E; Kataoka K; Nakamura T; Fukuda M; Tokutomi Y; Nako H; Ogawa H; Kim-Mitsuyama S
J Hypertens; 2010 Jul; 28(7):1554-65. PubMed ID: 20375908
[TBL] [Abstract][Full Text] [Related]
5. Feasibility of fluorescence energy transfer system for imaging the renoprotective effects of aliskiren in diabetic mice.
Kidokoro K; Satoh M; Itano S; Kuwabara A; Sasaki T; Kashihara N
J Renin Angiotensin Aldosterone Syst; 2016; 17(2):1470320315625704. PubMed ID: 27216079
[TBL] [Abstract][Full Text] [Related]
6. Aliskiren in combination with valsartan exerts synergistic protective effects against ventricular remodeling after myocardial infarction in mice.
Higashikuni Y; Takaoka M; Iwata H; Tanaka K; Hirata Y; Nagai R; Sata M
Hypertens Res; 2012 Jan; 35(1):62-9. PubMed ID: 21833001
[TBL] [Abstract][Full Text] [Related]
7. Hemodynamic and hormonal changes to dual renin-angiotensin system inhibition in experimental hypertension.
Moniwa N; Varagic J; Ahmad S; VonCannon JL; Simington SW; Wang H; Groban L; Brosnihan KB; Nagata S; Kato J; Kitamura K; Gomez RA; Lopez ML; Ferrario CM
Hypertension; 2013 Feb; 61(2):417-24. PubMed ID: 23232645
[TBL] [Abstract][Full Text] [Related]
8. Effects of mycophenolate mofetil, valsartan and their combined therapy on preventing podocyte loss in early stage of diabetic nephropathy in rats.
Zhang Y; Chen B; Hou XH; Guan GJ; Liu G; Liu HY; Li XG
Chin Med J (Engl); 2007 Jun; 120(11):988-95. PubMed ID: 17624267
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of aliskiren and valsartan in hypertensive patients with albuminuria: a randomized parallel-group study.
Spanos G; Kalaitzidis R; Karasavvidou D; Pappas K; Siamopoulos KC
J Renin Angiotensin Aldosterone Syst; 2013 Dec; 14(4):315-21. PubMed ID: 23132848
[TBL] [Abstract][Full Text] [Related]
10. Aliskiren reduces myocardial ischemia-reperfusion injury by a bradykinin B2 receptor- and angiotensin AT2 receptor-mediated mechanism.
Koid SS; Ziogas J; Campbell DJ
Hypertension; 2014 Apr; 63(4):768-73. PubMed ID: 24420538
[TBL] [Abstract][Full Text] [Related]
11. A reduction of unilateral ureteral obstruction-induced renal fibrosis by a therapy combining valsartan with aliskiren.
Wu WP; Chang CH; Chiu YT; Ku CL; Wen MC; Shu KH; Wu MJ
Am J Physiol Renal Physiol; 2010 Nov; 299(5):F929-41. PubMed ID: 20685818
[TBL] [Abstract][Full Text] [Related]
12. Renin inhibitor aliskiren improves impaired nitric oxide bioavailability and protects against atherosclerotic changes.
Imanishi T; Tsujioka H; Ikejima H; Kuroi A; Takarada S; Kitabata H; Tanimoto T; Muragaki Y; Mochizuki S; Goto M; Yoshida K; Akasaka T
Hypertension; 2008 Sep; 52(3):563-72. PubMed ID: 18645051
[TBL] [Abstract][Full Text] [Related]
13. Aliskiren improves insulin resistance and ameliorates diabetic renal vascular complications in STZ-induced diabetic rats.
Gandhi S; Srinivasan B; Akarte AS
J Renin Angiotensin Aldosterone Syst; 2013 Mar; 14(1):3-13. PubMed ID: 22791702
[TBL] [Abstract][Full Text] [Related]
14. Aliskiren and Valsartan reduce myocardial AT1 receptor expression and limit myocardial infarct size in diabetic mice.
Ye Y; Qian J; Castillo AC; Perez-Polo JR; Birnbaum Y
Cardiovasc Drugs Ther; 2011 Dec; 25(6):505-15. PubMed ID: 21987107
[TBL] [Abstract][Full Text] [Related]
15. Intrarenal renin-angiotensin system mediates fatty acid-induced ER stress in the kidney.
Li C; Lin Y; Luo R; Chen S; Wang F; Zheng P; Levi M; Yang T; Wang W
Am J Physiol Renal Physiol; 2016 Mar; 310(5):F351-63. PubMed ID: 26672616
[TBL] [Abstract][Full Text] [Related]
16. Schisandra chinensis fruit extract attenuates albuminuria and protects podocyte integrity in a mouse model of streptozotocin-induced diabetic nephropathy.
Zhang M; Liu M; Xiong M; Gong J; Tan X
J Ethnopharmacol; 2012 May; 141(1):111-8. PubMed ID: 22353431
[TBL] [Abstract][Full Text] [Related]
17. Aliskiren, an orally effective renin inhibitor, provides antihypertensive efficacy alone and in combination with valsartan.
Pool JL; Schmieder RE; Azizi M; Aldigier JC; Januszewicz A; Zidek W; Chiang Y; Satlin A
Am J Hypertens; 2007 Jan; 20(1):11-20. PubMed ID: 17198906
[TBL] [Abstract][Full Text] [Related]
18. Hormonal and hemodynamic effects of aliskiren and valsartan and their combination in sodium-replete normotensive individuals.
Azizi M; Ménard J; Bissery A; Guyene TT; Bura-Rivière A
Clin J Am Soc Nephrol; 2007 Sep; 2(5):947-55. PubMed ID: 17702736
[TBL] [Abstract][Full Text] [Related]
19. Dual inhibition of the renin system by aliskiren and valsartan.
Oparil S; Yarows SA; Patel S; Zhang J; Satlin A
Lancet; 2007 Sep; 370(9593):1126-7. PubMed ID: 17905160
[No Abstract] [Full Text] [Related]
20. Effects of renin-angiotensin-aldosterone system blockade on chlorhexidine gluconate-induced sclerosing encapsulated peritonitis in rats.
Koçak G; Azak A; Astarcı HM; Huddam B; Karaca G; Ceri M; Can M; Sert M; Duranay M
Ther Apher Dial; 2012 Feb; 16(1):75-80. PubMed ID: 22248199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
